Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jeremy Bender M.B.A., Ph.D. | CEO, President & Director | 1.05M | -- | 1971 |
| Mr. Charles N. York II, M.B.A. | COO, CFO & Secretary | 760k | -- | 1977 |
| Mr. Adam Dubow J.D. | General Counsel and Chief Compliance Officer | 608.2k | -- | 1967 |
| Mr. John Stubenrauch Ph.D. | Chief Technology Officer | -- | -- | -- |
| Ms. Jaa Roberson | Chief People Officer | -- | -- | -- |
| Dr. Davy Chiodin Ph.D., Pharm.D. | Chief Development Officer | -- | -- | -- |
| Ms. Lauren Merendino M.B.A. | Chief Commercial Officer | -- | -- | 1976 |
| Dr. Elly Barry M.D. | Chief Medical Officer | -- | -- | -- |
Day One Biopharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 181
Description
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available